Pacmilimab by CytomX Therapeutics for Esophageal Cancer: Likelihood of Approval

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Esophageal Cancer.

Source link
#Pacmilimab #CytomX #Therapeutics #Esophageal #Cancer #Likelihood #Approval